View of Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China

View of Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China

Return to Article Details Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China Download Download PDF